Online citations, reference lists, and bibliographies.
← Back to Search

Monitoring Of Chemotherapy Response In Malignant Pleural Mesothelioma Using Fluorodeoxyglucose Positron Emission Tomography.

T. Kimura, K. Koyama, S. Kudoh, J. Kawabe, N. Yoshimura, S. Mitsuoka, S. Shiomi, K. Hirata
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
We report a 56-year-old man who underwent monitoring of the response to chemotherapy of malignant pleural mesothelioma (MPM). (8)F-fluoro-2-deoxy-(D)-glucose positron emission tomography (FDG-PET) and computed tomography (CT) were performed prior to chemotherapy and after the first and second courses of chemotherapy. The tumor lesion exhibited shrinkage on CT and a decrease in the standardized uptake value (SUV) max after the first course of chemotherapy, but exhibited size enlargement and an increase in SUV max after the second course of chemotherapy. These findings suggest that results of quantification of metabolic response by FDG-PET are related to the objective response as determined by CT in patients with MPM.
This paper references
10.1016/J.LUNGCAN.2005.03.006
Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging.
H. Steinert (2005)
2-Fluoro-2deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients
S. G. Swisher (2004)
10.2967/jnumed.108.057307
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
R. Wahl (2009)
10.1097/MNM.0b013e328310b3ba
Dual time point FDG PET for evaluation of malignant pleural mesothelioma
Y. Yamamoto (2009)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
2 - Fluoro2deoxyD - glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma
S. G. Swisher (2004)
18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.
L. Kostakoglu (2003)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
2005)Proceedings of American Society of Clinical Oncology Annual Meeting. Vol 23, No. 16S, Part I of II (June 1 Supplement), (abstract 7066)
R. M. Flores (2005)
Combined FDGPET / CT in response evaluation of malignant pleural mesothelioma
P. Veit-Haibach (2010)
10.1002/cncr.20585
2‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma
S. Swisher (2004)
10.1016/j.lungcan.2009.04.015
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
P. Veit-Haibach (2010)
RESEARCH ARTICLE Prognostic Value of 18 F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P. Therasse (2000)
Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
V. Gerbaudo (2002)
10.1016/S0959-8049(99)00229-4
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H. Young (1999)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.3816/CLC.2009.n.033
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
Brad E Wilcox (2009)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
Utility of integrated computed tomography
M. C. Aubry (2009)
10.1111/j.1440-1843.2005.00714.x
Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma
D. Sterman (2005)
10.1111/j.1440-1843.2005.00694.x
Pathogenesis of malignant pleural mesothelioma
M. Jaurand (2005)
10.1378/CHEST.122.6.1918
Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion.
N. Gupta (2002)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.1056/NEJM200007273430404
Preoperative staging of non-small-cell lung cancer with positron-emission tomography.
R. Pieterman (2000)
10.1200/JCO.2005.23.16_SUPPL.7177
Monitoring of chemotherapy response in multiple disseminated malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography
T. Kimura (2005)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1007/s11307-009-0203-6
Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
10.1007/s00259-010-1704-x
FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival
V. Gerbaudo (2010)
10.1097/RLI.0b013e3181817b3d
Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma: Initial Results
C. Plathow (2008)
10.1200/JCO.1998.16.6.2142
Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.
J. Vansteenkiste (1998)
10.2169/INTERNALMEDICINE.47.1462
Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.
T. Kimura (2008)
10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4
Whole body positron emission tomography in the treatment of Hodgkin disease
B. Hültenschmidt (2001)
10.1007/s11307-009-0212-5
Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease
A. Mavi (2009)
10.1200/JCO.2003.07.054
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer.
M. M. Mac Manus (2003)
10.1378/CHEST.125.2.489
Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.
B. Duysinx (2004)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
H. Watanabe (2009)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
10.1097/00005382-200605000-00006
Preoperative Evaluation of Patients With Malignant Pleural Mesothelioma: Role of Integrated CT-PET Imaging
M. Truong (2006)
10.1200/JCO.2001.19.1.111
Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
V. Kalff (2001)



Semantic Scholar Logo Some data provided by SemanticScholar